Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05966883 · ClinicalTrials.gov registry record

SpermQT Prospective Observational Trial

A clinical trial of Male Infertility, sponsored by Inherent Biosciences.

Active
Registry status
1,000
Enrollment target
6
Study locations

NCT05966883 is a study of Male Infertility that is active but no longer recruiting, run by Inherent Biosciences. The registered enrollment target is 1,000 participants, above the 433-participant average among 8 other Male Infertility trials with a reported enrollment target (131% higher). The trial reports 6 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05966883, a study of Male Infertility, is active but no longer recruiting, sponsored by Inherent Biosciences.

ACTIVE NOT RECRUITING
Registry status
1,000 participants
Enrollment target
6
Study locations

Study Summary

The goal of the study is to validate the ability of the Epigenetic Sperm Quality Test (SpermQT) to assess a man's sperm quality and corresponding success of infertility treatments.

Conditions Studied

Study Locations (6)

California

  • Male Fertility and Sexual Medicine Specialists - San Diego

Colorado

  • Shady Grove Fertility - Greenwood Village

Connecticut

  • Yale Medicine - Orange

Massachusetts

  • Boston IVF - Waltham

Texas

  • Inception Fertility, LLC - Houston

Washington

  • University of Washington - Seattle

Trial Details

FieldValue
Enrollment Target 1,000 participants
Start Date 2023-01-01
Est. Completion 2026-09-30

Sponsor

Inherent Biosciences

1 total trials

What the Registry Record Tells You About NCT05966883

The ClinicalTrials.gov registry entry for NCT05966883 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 433-participant average among 8 other Male Infertility trials with a reported enrollment target (131% higher). The listed sponsor is Inherent Biosciences, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Male Infertility appearing as the primary indexed condition, and to 0 interventions.

NCT05966883 reports 6 study locations spanning 6 distinct geographic areas - top geographies include California, Colorado, Connecticut.

Frequently Asked Questions

What is clinical trial NCT05966883 about?

NCT05966883 is a clinical study titled "SpermQT Prospective Observational Trial". The goal of the study is to validate the ability of the Epigenetic Sperm Quality Test (SpermQT) to assess a man's sperm quality and corresponding success of infertility treatments.

What is the current status of trial NCT05966883?

This trial is currently active not recruiting. The enrollment target is 1,000 participants. The study started on 2023-01-01. Estimated completion is 2026-09-30.

What conditions does trial NCT05966883 study?

This clinical trial studies the following conditions: Male Infertility.

Who is sponsoring clinical trial NCT05966883?

This trial is sponsored by Inherent Biosciences, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05966883 being conducted?

This trial has 6 study locations across California, Colorado, Connecticut, Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Male Infertility

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.